ULTI Ultimovacs

Ultimovacs ASA – Disclosure of voting rights of Extraordinary General Meeting

Ultimovacs ASA – Disclosure of voting rights of Extraordinary General Meeting

Oslo, January 8, 2025: In connection with the Extraordinary General Meeting of Ultimovacs ASA to be held on January 9, 2025, Jónas Einarsson, Chair of the Board of Directors, has so far received proxy-based voting rights without voting instructions for 8,652,094 shares, representing 25.15% of the total voting rights in the company.

The proxies are only valid for the Extraordinary General Meeting on January 9, 2025.

This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

For further information, please see or contact:

Jónas Einarsson, Chair of the Board of Directors of Ultimovacs ASA

Email:

Phone:  355

Hans Vassgård Eid, CFO and Interim CEO, Ultimovacs ASA

Email:

Phone:



EN
08/01/2025

Underlying

ULTIUltimovacs

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Ultimovacs

 PRESS RELEASE
Free
ULTI ULTIMOVACS

Zelluna ASA [ZLNA]: Notice of Annual General Meeting on April 29, 2025

Zelluna ASA [ZLNA]: Notice of Annual General Meeting on April 29, 2025 Oslo, April 04, 2025, the Board of Directors hereby calls for the Annual General Meeting of Zelluna ASA at 14:00 CET on April 29, 2025.  The General Meeting will be held electronically. For participation, please log in at . All documents regarding the Annual General Meeting are available at the Company’s website: For further information, please contact: Anders Tuv, Chairman of the Board of Directors of Zelluna ASAEmail: Phone: Namir Hassan, CEO, Zelluna ASAEmail: Phone: Hans Vassgård Eid, CFO, Zelluna ASA Ema...

3h / 39m 1 EN
 PRESS RELEASE
Free
ULTI ULTIMOVACS

Zelluna ASA [ZLNA]: Annual Report 2024

Zelluna ASA [ZLNA]: Annual Report 2024 Oslo, Norway, 02 April, 2025 - Zelluna ASA, a company pioneering allogeneic ‘off the shelf’ T Cell Receptor based Natural Killer (TCR-NK) cells for the treatment of cancer, announces that the Board of Directors of Zelluna ASA has approved the Annual Report for 2024.  Please find a PDF version of the annual report, as well as the report in European Single Electronic Format (ESEF), as attachments to this release. The Annual Report is also available at the company's website: This information is subject to the disclosure requirements pursuant to Section...

April 2, 2025 1 EN
ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Alexander Krämer
04/01/25 April 1, 2025 1 EN
 PRESS RELEASE
Free
ULTI ULTIMOVACS

Zelluna ASA [ZLNA]: Ex reverse share split today

Zelluna ASA [ZLNA]: Ex reverse share split today Oslo, Norway, 1 April 2025 Issuer name: Zelluna ASAEx. date: 1 April 2025Type of corporate action: Reverse share split Other information:Reverse split ratio – ten (10) old shares give one (1) new share.New par value of NOK 1 per shareNew ISIN is NO 001 3524942. For further information, please contact: Hans Vassgård Eid, CFO, Zelluna ASAEmail: Phone: About Zelluna ASAZelluna’s mission is to deliver transformative treatments with the capacity to cure advanced solid cancers, in a safe and cost-efficient manner, to patients on a global sca...

April 1, 2025 1 EN
 PRESS RELEASE
Free
ULTI ULTIMOVACS

Zelluna ASA [ZLNA]: Registration of reverse share split

Zelluna ASA [ZLNA]: Registration of reverse share split Oslo, Norway, 31 March, 2025 Reference is made to the stock exchange notice published by the Zelluna ASA (the "Company") on 27 March 2025 with key information concerning a reverse share split in the ratio of 10:1. The reverse share split has today been registered with the Norwegian Register of Business Enterprises. After the registration of the reverse share split, the new number of outstanding shares in the Company is 20,227,066, each with a par value of NOK 1. For further information, please contact: Hans Vassgård Eid, CFO, Zellu...

March 31, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch